KSKarina Marques Milhomem de Sousa

Karina Marques Milhomem de Sousa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karina Marques Milhomem de Sousa has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Leucoencefalopatia multifocal progressiva e a associação com o vírus JC (John Cunningham): Uma análise bibliográfica que aborda do diagnóstico às estratégias terapêuticas

    by João Victor Carvalho da Paz, Solano Kaluangila Andrelino Santiago, Thamires Mendes Gomes, Johana Mirela Shikama Silveira, Letícia Chaves Véras Do Rosário, João Gabriel Gomes Araújo, Gabriel Mesquita Almeida de Sousa, Carla Castro Rodrigues, Lucas Frota Beckman, Alexandre Augusto Gomes Alves, et al.

    Progressive Multifocal Leukoencephalopathy (PML) is a neurological condition caused by the JC virus, predominantly impacting the central nervous system. Its aggressiveness is evident in patients with immunological compromise, such as those with HIV/AIDS, transplants or those undergoing specific therapies. The objective of this work is to analyze what the most recent literature presents on this topic, considering its relevance today. In this way, we intend to bring to light topics that can improve the life expectancy of these patients." A systematic and quantitative review of the literature was conducted, using platforms such as PubMed, SciELO and Google Scholar until 2023. Exclusion criteria were applied to select retrospective or prospective non-randomized studies for inclusion in the meta-analysis. When the JC virus is reanimated in immunosuppressed hosts, it plays a very important role in the development of PML. Its spectrum of manifestations ranges from demyelination to focal neurological deficits, detectable through examinations imaging techniques such as CT and MRI. Despite efforts, an effective treatment for PML has not yet been identified. Current strategies aim to strengthen the adaptive immune response, such as immediate initiation of antiretroviral therapy in patients with HIV. Research is exploring therapies involving HIV vaccines. dendritic cells and other approaches, but more research is needed. PML remains deadly in most cases. Early detection and a multidisciplinary approach are key to management. Healthcare professionals must be vigilant regarding neurological symptoms in immunosuppressed patients, while awareness and regular monitoring are crucial for patients.

  • Open Access

    Revisão dos distúrbios de deficiência de tiamina: encefalopatia de Wernicke e psicose de Korsakoff, formando a Síndrome de Wernicke-Korsakoff

    by João Victor Carvalho da Paz, Lucas Frota Beckman, Brenda Santana Araujo Giacomo, Letícia Chaves Véras Do Rosário, Anne Dollores Sousa Jardim Nascimento, Vanessa Campos Silva Pinheiro, Mariah Aparecida Pessoa Luz, Laize dos Santos Ribeiro, Liana Maria Silva Santos, Christian Silva Pinto, et al.

    Wernicke's encephalopathy (WE) and Korsakoff syndrome (KS) are distinct neurological disorders that may have overlapping clinical features. Due to the overlap, they are collectively referred to as Wernicke-Korsakoff syndrome. WE has been associated with thiamine-induced diencephalic and midbrain dysfunction. WE usually presents with confusion, ophthalmoplegia, nystagmus, and gait ataxia (Wernicke's triad), although they do not always occur together. Although WE occurs mainly in alcoholics, other etiologies must also be considered, such as after bariatric surgery. Early diagnosis and intravenous thiamine therapy are essential to prevent WE complications and reduce morbidity and mortality. Therefore, allowing physicians and patients to understand WE is crucial for early diagnosis and treatment. Therefore, the narrative review aims to provide the latest information on WE by reviewing articles published between April 2015 and April 2022 on the etiology, pathophysiology, diagnosis, and management updates of WE. Literature searches were performed using EMBASE, PubMed, Google Scholar, Google, and Scopus search engines.

  • Open Access

    Síndrome Inflamatória Multissistêmica em Crianças (MIS-C) associada ao SARS-CoV-2 (COVID – 2019): uma revisão sistemática

    by João Victor Carvalho da Paz, Brunna Renata de Abreu As, Thiara Araújo Fernandes Ribeiro, Lucas Barros Fonseca, Francisco Airton Veras de Araújo Júnior, Tereza Cristina Barbosa Ribeiro Do Vale, Bianca Regina Martins Nunes Araújo, Ana Paula Diniz Alves, Alexandre Augusto Gomes Alves, Beatriz da Cruz Alves, et al.

    Introduction: Children's multisystem inflammatory syndrome (MIS-C), also known as pediatric inflammatory multisystem syndrome, is a dangerous new childhood illness that is temporarily associated with coronavirus disease 2019 (COVID-19). Our aim was to describe the typical presentation and outcomes of children diagnosed with this hyperinflammatory condition. Method: We conducted a systematic review to report the clinical signs and symptoms, laboratory findings, imaging results, and outcomes of subjects with MIS-C. We searched four medical databases to encompass studies featuring 2020 MIS-C. Results: Fever was documented in nearly all patients (99.4%), usually lasting at least 5 days (27.0%). Most (85.6%) had gastrointestinal symptoms, mainly abdominal pain (58.4%), vomiting (57.5%) and diarrhea (50.4%). Cardiovascular manifestations were found in 79.3% of patients (307/387). Tachycardia (194/253; 76.7%), hemodynamic shock or hypotension (416/695; 59.9%), myocarditis (128/309; 41.4%) and mild or moderate decrease in left ventricular ejection fraction (LVEF between 30 and 55%; 40.4%) were frequently observed cardiovascular abnormalities. Discussion: Children typically show signs/symptoms of MIS-C three to four weeks after infection with COVID-19 and many rapidly progress to shock and cardiorespiratory failure. Children will generally survive this hyperinflammatory condition with the administration of IVIG, steroids, a multidisciplinary team of healthcare professionals, and in some cases, immunomodulatory agents. Conclusion: More epidemiological, clinical, immunological and genetic research is needed, as well as long-term follow-up studies of patients with PIMS-TS/MIS(-C).